Mario Danek

Mario Danek is the Founder and Chief Technology Officer (CTO) of Qnovia, Inc., a pharmaceutical company established in 2018 that focuses on developing innovative inhaled therapeutics for smoking cessation and other medical applications. Under his leadership, Qnovia aims to tackle public health issues related to smoking, which remains a leading cause of preventable death globally, with approximately eight million deaths attributed to tobacco use each year.13

Background and Experience

Danek has a strong background in company launches and growth strategies, having been involved in various roles that encompass sales, hardware manufacturing, product development, and FDA regulatory strategy. He is recognized as an inventor with several granted patents, showcasing his commitment to innovation in drug delivery systems.25

Vision for Qnovia

In his role, Danek emphasizes the need for novel approaches to nicotine replacement therapies (NRTs), arguing that existing products have not significantly improved cessation rates over the past two decades. He believes that Qnovia's proprietary drug delivery platform can provide effective solutions for smokers seeking to quit by addressing both pharmacokinetics and user experience.34

Current Initiatives

Qnovia recently received FDA clearance for its lead product, the RespiRx Nicotine Inhaler, which is set to enter clinical trials aimed at evaluating its effectiveness compared to traditional nicotine inhalers and combustible cigarettes. This initiative reflects Danek's commitment to advancing public health through innovative therapeutic options.12

Danek's leadership at Qnovia positions him as a key player in the ongoing effort to reduce smoking-related health risks and improve treatment outcomes for millions of smokers worldwide.